GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Inventories, Raw Materials & Components

Oruka Therapeutics (FRA:HQ1) Inventories, Raw Materials & Components : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Inventories, Raw Materials & Components?

Oruka Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was €0.00 Mil.


Oruka Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Oruka Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Inventories, Raw Materials & Components Chart

Oruka Therapeutics Annual Data
Trend Dec24
Inventories, Raw Materials & Components
-

Oruka Therapeutics Semi-Annual Data
Dec24
Inventories, Raw Materials & Components -

Oruka Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Oruka Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines